EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 409 filers reported holding EXELIXIS INC in Q2 2024. The put-call ratio across all filers is 0.63 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,532,993 | -31.6% | 68,224 | -27.7% | 0.00% | -100.0% |
Q1 2024 | $2,240,349 | +66.3% | 94,410 | +68.1% | 0.00% | – |
Q4 2023 | $1,347,064 | -48.6% | 56,151 | -53.2% | 0.00% | -100.0% |
Q3 2023 | $2,622,685 | +1.0% | 120,031 | -11.6% | 0.00% | 0.0% |
Q2 2023 | $2,595,979 | +15.3% | 135,844 | +17.1% | 0.00% | 0.0% |
Q1 2023 | $2,251,162 | -50.7% | 115,979 | -59.2% | 0.00% | 0.0% |
Q4 2022 | $4,562,081 | -3.6% | 284,419 | -5.7% | 0.00% | -50.0% |
Q3 2022 | $4,731,000 | -30.5% | 301,678 | -7.8% | 0.00% | 0.0% |
Q2 2022 | $6,812,000 | -35.7% | 327,173 | -30.0% | 0.00% | -33.3% |
Q1 2022 | $10,594,000 | +36.6% | 467,247 | +10.1% | 0.00% | +50.0% |
Q4 2021 | $7,757,000 | -67.7% | 424,343 | -62.7% | 0.00% | -60.0% |
Q3 2021 | $24,031,000 | +161.9% | 1,136,737 | +125.7% | 0.01% | +150.0% |
Q2 2021 | $9,174,000 | -22.7% | 503,545 | -4.1% | 0.00% | -33.3% |
Q1 2021 | $11,863,000 | +17.3% | 525,111 | +4.2% | 0.00% | +50.0% |
Q4 2020 | $10,113,000 | -25.2% | 503,867 | -8.9% | 0.00% | -50.0% |
Q3 2020 | $13,528,000 | -4.0% | 553,319 | -6.8% | 0.00% | 0.0% |
Q2 2020 | $14,098,000 | +34.9% | 593,842 | -2.2% | 0.00% | 0.0% |
Q1 2020 | $10,453,000 | -15.2% | 607,005 | -13.2% | 0.00% | +33.3% |
Q4 2019 | $12,327,000 | -10.8% | 699,616 | -13.3% | 0.00% | -25.0% |
Q3 2019 | $13,826,000 | -40.5% | 806,683 | -25.8% | 0.00% | -42.9% |
Q2 2019 | $23,233,000 | -69.5% | 1,087,186 | -66.1% | 0.01% | -69.6% |
Q1 2019 | $76,266,000 | +409.1% | 3,204,443 | +320.7% | 0.02% | +360.0% |
Q4 2018 | $14,982,000 | +77.3% | 761,670 | +59.7% | 0.01% | +150.0% |
Q3 2018 | $8,451,000 | -87.3% | 476,910 | -84.6% | 0.00% | -90.0% |
Q2 2018 | $66,464,000 | -21.4% | 3,088,439 | -19.1% | 0.02% | -20.0% |
Q1 2018 | $84,571,000 | -9.5% | 3,818,088 | +24.2% | 0.02% | -7.4% |
Q4 2017 | $93,476,000 | +26.8% | 3,074,863 | +1.1% | 0.03% | +17.4% |
Q3 2017 | $73,723,000 | +34.3% | 3,042,694 | +36.5% | 0.02% | +27.8% |
Q2 2017 | $54,889,000 | +73.5% | 2,228,517 | +52.6% | 0.02% | +80.0% |
Q1 2017 | $31,642,000 | +288.2% | 1,460,194 | +167.1% | 0.01% | +233.3% |
Q4 2016 | $8,152,000 | +33.6% | 546,740 | +14.6% | 0.00% | +50.0% |
Q3 2016 | $6,104,000 | +141.7% | 477,286 | +47.6% | 0.00% | +100.0% |
Q2 2016 | $2,525,000 | +216.0% | 323,341 | +61.8% | 0.00% | – |
Q1 2016 | $799,000 | -27.0% | 199,859 | +3.0% | 0.00% | – |
Q4 2015 | $1,095,000 | +16.0% | 194,004 | +15.2% | 0.00% | – |
Q3 2015 | $944,000 | +148.4% | 168,354 | +66.3% | 0.00% | – |
Q2 2015 | $380,000 | +25.0% | 101,214 | -14.2% | 0.00% | – |
Q1 2015 | $304,000 | +406.7% | 117,958 | +152.7% | 0.00% | – |
Q4 2014 | $60,000 | -31.8% | 46,682 | -19.2% | 0.00% | – |
Q3 2014 | $88,000 | -89.4% | 57,760 | -76.3% | 0.00% | – |
Q2 2014 | $827,000 | +389.3% | 243,757 | +412.1% | 0.00% | – |
Q1 2014 | $169,000 | -96.1% | 47,602 | -93.3% | 0.00% | -100.0% |
Q4 2013 | $4,345,000 | +8.1% | 708,782 | +2.6% | 0.00% | 0.0% |
Q3 2013 | $4,020,000 | +15.4% | 690,792 | -10.0% | 0.00% | 0.0% |
Q2 2013 | $3,485,000 | – | 767,572 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 15,001,073 | $320,572,000 | 64.48% |
Sargent Investment Group, LLC | 432,125 | $9,235,000 | 4.22% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 443,534 | $9,483,000 | 3.52% |
Bellevue Group AG | 3,878,800 | $82,890,000 | 1.42% |
CAPITAL MANAGEMENT CORP /VA | 237,855 | $5,083,000 | 1.40% |
Orbimed Advisors | 3,912,900 | $83,619,000 | 1.30% |
Portolan Capital Management | 540,590 | $11,552,000 | 1.24% |
TEALWOOD ASSET MANAGEMENT INC | 139,347 | $2,978,000 | 1.21% |
Signition LP | 84,120 | $1,798,000,000 | 1.18% |
Penn Capital Management Company, LLC | 529,630 | $11,318,000 | 1.12% |